Apremilast efficacy and safety in elderly psoriasis patients over a 48-weeks period

Psoriasis management embraces many difficult tasks, with frequent challenges in case of elderly patients. The treatment of this chronic condition is particularly complicated in elderly for additional factors such as common multiple comorbidities and related polypharmacy, infection and cancer susceptibility. About 17-25% of elderly psoriatic patients suffer from a moderate-to-severe disease, requiring a systemic treatment which is often impeded due to contraindications, drug interactions and adverse events (AEs).